[go: up one dir, main page]

SI2451438T1 - Farmacevtski sestavek za inhibitor virusne proteaze hepatitisa C - Google Patents

Farmacevtski sestavek za inhibitor virusne proteaze hepatitisa C

Info

Publication number
SI2451438T1
SI2451438T1 SI201030565T SI201030565T SI2451438T1 SI 2451438 T1 SI2451438 T1 SI 2451438T1 SI 201030565 T SI201030565 T SI 201030565T SI 201030565 T SI201030565 T SI 201030565T SI 2451438 T1 SI2451438 T1 SI 2451438T1
Authority
SI
Slovenia
Prior art keywords
hepatitis
pharmaceutical composition
protease inhibitor
viral protease
viral
Prior art date
Application number
SI201030565T
Other languages
English (en)
Inventor
Feng-Jing Chen
Robert J. Schwabe
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of SI2451438T1 publication Critical patent/SI2451438T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201030565T 2009-07-07 2010-07-01 Farmacevtski sestavek za inhibitor virusne proteaze hepatitisa C SI2451438T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22350709P 2009-07-07 2009-07-07
EP10731685.3A EP2451438B8 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor
PCT/US2010/040734 WO2011005646A2 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor

Publications (1)

Publication Number Publication Date
SI2451438T1 true SI2451438T1 (sl) 2014-04-30

Family

ID=43245003

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030565T SI2451438T1 (sl) 2009-07-07 2010-07-01 Farmacevtski sestavek za inhibitor virusne proteaze hepatitisa C

Country Status (35)

Country Link
US (1) US9034831B2 (sl)
EP (1) EP2451438B8 (sl)
JP (1) JP5607736B2 (sl)
KR (1) KR101685941B1 (sl)
CN (1) CN102470103B (sl)
AP (1) AP2011005979A0 (sl)
AR (1) AR077393A1 (sl)
AU (1) AU2010270783B2 (sl)
BR (1) BR112012000287B8 (sl)
CA (1) CA2767692C (sl)
CL (1) CL2012000054A1 (sl)
CO (1) CO6480980A2 (sl)
DK (1) DK2451438T3 (sl)
EA (1) EA023433B1 (sl)
EC (1) ECSP12011624A (sl)
ES (1) ES2464367T3 (sl)
GE (1) GEP20146016B (sl)
HR (1) HRP20140445T1 (sl)
IL (1) IL216098A (sl)
MA (1) MA33491B1 (sl)
ME (1) ME01718B (sl)
MX (1) MX2011013824A (sl)
MY (1) MY154683A (sl)
NZ (1) NZ596928A (sl)
PE (1) PE20120322A1 (sl)
PL (1) PL2451438T3 (sl)
PT (1) PT2451438E (sl)
RS (1) RS53209B (sl)
SG (1) SG177569A1 (sl)
SI (1) SI2451438T1 (sl)
TN (1) TN2012000009A1 (sl)
TW (1) TWI490216B (sl)
UA (1) UA104195C2 (sl)
UY (1) UY32760A (sl)
WO (1) WO2011005646A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
PL2451438T3 (pl) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C
JP2013508425A (ja) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bi201335、インターフェロンアルファおよびリバビリンを含むhcvの併用療法のための投薬処置計画
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2802313A1 (en) * 2012-01-12 2014-11-19 Boehringer Ingelheim International GmbH Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
US9732076B2 (en) * 2013-03-15 2017-08-15 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
CA3140164A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
US5329976A (en) 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
ATE198041T1 (de) 1993-09-28 2000-12-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
JPH11505257A (ja) 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
EP0989851B1 (en) * 1997-07-29 2002-10-02 PHARMACIA & UPJOHN COMPANY Self-emulsifying formulation for acidic lipophilic compounds
ES2174462T3 (es) 1997-07-29 2002-11-01 Upjohn Co Formulacion autoestimulante para compuestos lipofilos.
NZ502569A (en) * 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2466851C (en) 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
WO2004093915A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
WO2004103996A1 (en) * 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
DE602005019700D1 (de) 2004-03-15 2010-04-15 Boehringer Ingelheim Int E, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
GEP20104926B (en) 2004-03-30 2010-03-25 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
JP5156374B2 (ja) * 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式hcvプロテアーゼインヒビターの調製方法
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
EA022272B1 (ru) 2008-11-21 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция эффективного ингибитора всг для перорального введения
PL2451438T3 (pl) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
ECSP12011624A (es) 2012-02-29
TW201114766A (en) 2011-05-01
PE20120322A1 (es) 2012-04-14
DK2451438T3 (da) 2014-03-10
TWI490216B (zh) 2015-07-01
WO2011005646A2 (en) 2011-01-13
KR20120059481A (ko) 2012-06-08
EP2451438B1 (en) 2014-02-26
MX2011013824A (es) 2012-01-30
EP2451438A2 (en) 2012-05-16
RS53209B (sr) 2014-06-30
US9034831B2 (en) 2015-05-19
US20110160149A1 (en) 2011-06-30
EA201200096A1 (ru) 2012-08-30
EA023433B1 (ru) 2016-06-30
MY154683A (en) 2015-07-15
IL216098A0 (en) 2012-01-31
TN2012000009A1 (en) 2013-09-19
JP5607736B2 (ja) 2014-10-15
BR112012000287B8 (pt) 2021-05-25
PT2451438E (pt) 2014-03-26
SG177569A1 (en) 2012-03-29
IL216098A (en) 2016-02-29
HRP20140445T1 (hr) 2014-06-20
UY32760A (es) 2011-02-28
AU2010270783B2 (en) 2013-06-27
WO2011005646A3 (en) 2011-12-22
NZ596928A (en) 2013-05-31
ES2464367T3 (es) 2014-06-02
UA104195C2 (ru) 2014-01-10
AR077393A1 (es) 2011-08-24
CN102470103A (zh) 2012-05-23
CA2767692C (en) 2017-03-07
PL2451438T3 (pl) 2014-07-31
CL2012000054A1 (es) 2012-10-12
MA33491B1 (fr) 2012-08-01
AP2011005979A0 (en) 2011-12-31
ME01718B (me) 2014-09-20
CA2767692A1 (en) 2011-01-13
JP2012532192A (ja) 2012-12-13
CN102470103B (zh) 2016-09-07
AU2010270783A1 (en) 2011-12-15
CO6480980A2 (es) 2012-07-16
KR101685941B1 (ko) 2016-12-13
BR112012000287A2 (pt) 2016-02-23
EP2451438B8 (en) 2014-04-09
GEP20146016B (en) 2014-01-27
BR112012000287B1 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
IL216098A0 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
HUS1500019I1 (hu) Hepatitisz C vírus inhibitorok
IL219516A0 (en) Hepatitis c virus inhibitors
IL219517A0 (en) Hepatitis c virus inhibitors
SG10201400235PA (en) Hepatitis c virus inhibitors
ZA201105722B (en) Hepatitis c virus inhibitors
IL215055A0 (en) Hepatitis c virus inhibitors
IL214939A0 (en) Hepatitis c virus inhibitors
EP2475256A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201107095B (en) Hepatitis c virus inhibitors
EP2512480A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201202631B (en) Hcv protease inhibitors
GB0908394D0 (en) Novel viral replication inhibitors
GB0913636D0 (en) Novel viral replication inhibitors
IL207459A (en) Hepatitis virus inhibitors c
ZA201008988B (en) Hcv protease inhibitors
IL216256A0 (en) A pharmaceutical composition
EP2504343A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
PL2389164T3 (pl) Kompozycje farmaceutyczne zawierające prolek inhibitora polimerazy HCV
EP2134336A4 (en) HIV PROTEASE INHIBITORS DERIVED FROM BENZOFURAN
SI2368890T1 (sl) Inhibitorji virusa hepatitisa C
SG2014011258A (en) Hcv protease inhibitors
HK1160858A (en) Hepatitis c virus inhibitors